Table 1 Base characteristics of patients before and after propensity score matching

Age

<.001

.065

< 50

369 (30.1)

218 (35.3)

151 (24.8)

198 (28.3)

88 (25.1)

110 (31.4)

≥50

858 (69.9)

399 (64.7)

459 (75.2)

502 (71.7)

262 (74.9)

240 (68.6)

Menopausal status

<.001

.111

Pre-

436 (35.5)

256 (41.5)

180 (29.5)

240 (34.3)

110 (31.4)

130 (37.1)

Post-

791 (64.5)

361 (58.5)

430 (70.5)

460 (65.7)

240 (68.6)

220 (62.9)

Tumor size, cm

<.001

.621

≤2

843 (68.7)

384 (62.2)

459 (75.2)

490 (70.0)

242 (69.1)

248 (70.9)

> 2

384 (31.3)

233 (37.8)

151 (24.8)

210 (30.0)

108 (30.9)

102 (29.1)

Node involvement

<.001

.135

Negative

1156 (94.2)

557 (90.3)

599 (98.2)

670 (95.7)

331 (94.6)

339 (96.9)

Positive

71 (5.8)

60 (9.7%)

11 (1.8)

30 (4.3)

19 (5.4)

11 (3.1)

Histology

<.001

.489

IDC

1059 (86.3)

582 (94.3)

477 (78.2)

629 (89.9)

319 (91.1)

310 (88.6)

ILC

50 (4.1)

21 (3.4)

29 (4.8)

37 (5.3)

17 (4.9)

20 (5.7)

Other

118 (9.6)

14 (2.3)

104 (17.0)

34 (4.8)

14 (4.0)

20 (5.7)

Grade

<.001

.171

Well

116 (9.4)

26 (4.2)

90 (14.8)

46 (6.6)

25 (7.1)

21 (6.0)

Moderately

683 (55.7)

342 (55.4)

341 (55.9)

463 (66.1)

229 (65.4)

234 (66.9)

Poorly

264 (21.5)

212 (34.4)

52 (8.5)

119 (17.0)

67 (19.1)

52 (14.9)

Unknown

164 (13.4)

37 (6.0)

127 (20.8)

72 (10.3)

29 (8.3)

43 (12.3)

Endocrine therapy

.002

.211

TAM

477 (38.9)

266 (43.1)

211 (34.6)

262 (37.4)

123 (35.1)

139 (39.7)

AI

750 (61.1)

351 (56.9)

399 (65.4)

438 (62.6)

227 (64.9)

211 (60.3)